No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening - PubMed (original) (raw)
No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening
Beverly E Hird et al. Arch Dis Child. 2014 Feb.
Abstract
Objective: Congenital adrenal hyperplasia (CAH) is not currently included in the UK newborn screening programme. We investigated the hypothesis that, owing to non-specificity of symptoms, a proportion of males affected by salt-wasting (SW) CAH have died in infancy without being diagnosed.
Design: Stored newborn screening blood spot samples were analysed for 17α-hydroxyprogesterone (17-OHP) in the following groups: Infants born in the North West of England, 1994 to 2006, who had died by 6 months age; (n=1198), a neonatal reference group (full-term n=100; preterm n=100) and a CAH positive control group. A newborn blood spot sample collected before diagnosis was available in 29/61 CAH patients recruited. SW CAH was present in 18/29 patients (16 males and 2 females). Samples from the deceased group with elevated 17-OHP were analysed for 8 common mutations in the 21-hydroxylase gene (CYP21A2).
Setting: North West of England.
Results: Grouped by gestational age, mean (maximum) blood spot 17-OHP in nmol/L was as follows. Deceased full-term n=279, 6 (107); deceased premature n=365, 28 (251); deceased unknown gestational age n=553, 13 (>394). In the SW positive control group, the lowest level of 17-OHP was 179 nmol/L and 14 had levels greater than the highest standard (>268 to >420 nmol/L). All samples from the deceased group with 17-OHP results >179 nmol/L (n=6) and a further 13 samples underwent mutation analysis. No mutations were identified.
Conclusions: Our findings do not support the hypothesis that, in our unscreened population, males affected by SW CAH are dying prior to diagnosis.
Keywords: 21-hydroxylase deficiency; Congenital adrenal hyperplasia; infant mortality; neonatal screening; newborn screening.
Similar articles
- Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia.
Votava F, Török D, Kovács J, Möslinger D, Baumgartner-Parzer SM, Sólyom J, Pribilincová Z, Battelino T, Lebl J, Frisch H, Waldhauser F; Middle European Society for Paediatric Endocrinology -- Congenital Adrenal Hyperplasia (MESPE-CAH) Study Group. Votava F, et al. Eur J Endocrinol. 2005 Jun;152(6):869-74. doi: 10.1530/eje.1.01929. Eur J Endocrinol. 2005. PMID: 15941926 - [Multicenter investigation on the impact of newborn infants' gestational age and birth weight on the level of 17α-hydroxyprogesterone].
Zhang Q, Wang B, Chen Y, Jiang D, Chen Y. Zhang Q, et al. Zhonghua Er Ke Za Zhi. 2014 Sep;52(9):706-9. Zhonghua Er Ke Za Zhi. 2014. PMID: 25476436 Chinese. - How many deaths can be prevented by newborn screening for congenital adrenal hyperplasia?
Grosse SD, Van Vliet G. Grosse SD, et al. Horm Res. 2007;67(6):284-91. doi: 10.1159/000098400. Epub 2007 Jan 3. Horm Res. 2007. PMID: 17199092 Review. - Analysis of the Screening Results for Congenital Adrenal Hyperplasia Involving 7.85 Million Newborns in China: A Systematic Review and Meta-Analysis.
Li Z, Huang L, Du C, Zhang C, Zhang M, Liang Y, Luo X. Li Z, et al. Front Endocrinol (Lausanne). 2021 Apr 23;12:624507. doi: 10.3389/fendo.2021.624507. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33967952 Free PMC article.
Cited by
- Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.
Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, Arlt W, Auchus RJ, Falhammar H, Flück CE, Guasti L, Huebner A, Kortmann BBM, Krone N, Merke DP, Miller WL, Nordenström A, Reisch N, Sandberg DE, Stikkelbroeck NMML, Touraine P, Utari A, Wudy SA, White PC. Claahsen-van der Grinten HL, et al. Endocr Rev. 2022 Jan 12;43(1):91-159. doi: 10.1210/endrev/bnab016. Endocr Rev. 2022. PMID: 33961029 Free PMC article. Review. - The next 150 years of congenital adrenal hyperplasia.
Turcu AF, Auchus RJ. Turcu AF, et al. J Steroid Biochem Mol Biol. 2015 Sep;153:63-71. doi: 10.1016/j.jsbmb.2015.05.013. Epub 2015 Jun 3. J Steroid Biochem Mol Biol. 2015. PMID: 26047556 Free PMC article. Review. - Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.
Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, Meyer-Bahlburg HFL, Miller WL, Murad MH, Oberfield SE, White PC. Speiser PW, et al. J Clin Endocrinol Metab. 2018 Nov 1;103(11):4043-4088. doi: 10.1210/jc.2018-01865. J Clin Endocrinol Metab. 2018. PMID: 30272171 Free PMC article. - Challenges in Assessing the Cost-Effectiveness of Newborn Screening: The Example of Congenital Adrenal Hyperplasia.
Grosse SD, Van Vliet G. Grosse SD, et al. Int J Neonatal Screen. 2020 Oct 25;6(4):82. doi: 10.3390/ijns6040082. Int J Neonatal Screen. 2020. PMID: 33239603 Free PMC article. Review. - The Cost-Effectiveness of Congenital Adrenal Hyperplasia Newborn Screening in Brazil: A Comparison Between Screened and Unscreened Cohorts.
de Miranda MC, Haddad LBP, Trindade E, Cassenote A, Hayashi GY, Damiani D, Costa FC, Madureira G, de Mendonca BB, Bachega TASS. de Miranda MC, et al. Front Pediatr. 2021 May 24;9:659492. doi: 10.3389/fped.2021.659492. eCollection 2021. Front Pediatr. 2021. PMID: 34109139 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical